Rating date
Jun 16, 2026
55 days ago
Abbott Laboratories (ABT) Stock Analysis
BUYABT Equity Research — BUY — June 2026
Desk view
BUY
5D move
—
Awaiting market data
Peer rank
28p
Research history
2026-08-072026-07-202026-07-012026-06-252026-06-182026-06-162026-06-082026-06-02+1 moreInvestment card · ABT
Over the trailing 12 months, ABT sustained a persistent bear trend. The stock opened at ~$132.85 in mid-June 2025 and declined steadily, punctuated by intermittent rallies that failed to hold. By late May 2026, the stock tested a low nea...
Desk rating
BUY
Tactical BUY · 12M BUY
Horizon
Long-term
Confidence
Medium
Invalidation
Margin compression persists if input costs (WTI at $95) and R&D spend outpace revenue growth.
Bias
BUY
Catalysts
- ABT is in a deep structural downtrend — the stock has lost ~33% from mid-2025 levels and remains well below both key moving averages.
- A short-term recovery bounce is in progress since mid-May, lifting the stock off its lows, but it has not yet broken above the 50-day SMA resistance (~$90.62).
- Momentum has improved sharply — RSI returned to neutral and MACD is on the verge of a bullish crossover for the first time in months.
Risks
- Margin compression persists if input costs (WTI at $95) and R&D spend outpace revenue growth.
- Competitive threats from Insulet’s Omnipod 5 100 mg/dL target option could pressure Libre’s market share in pumps.
- A recession or further consumer sentiment erosion (currently 49.8) could hurt nutrition and diagnostics volumes.
Market chart
Price context alongside the research narrative.
ABT Research Note
Full desk note for Jun 16, 2026. Use tabs for catalysts, valuation and risks, or open the full note.
WebserviceX · Agentic Research Desk
ABT Equity Research Note
ABT Stock Rating Summary
ABT bias
BUY
Horizon
Long-term
ABT key risk
Margin compression persists if input costs (WTI at $95) and R&D spend outpace revenue growth.
ABT catalyst watch
ABT is in a deep structural downtrend — the stock has lost ~33% from mid-2025 levels and remains well below both key moving averages.
Invalidation
Margin compression persists if input costs (WTI at $95) and R&D spend outpace revenue growth.
Confidence
Medium
How the call aged · 5D
—Awaiting market dataPeer 28pExpandCollapse
How the call aged · 5D
—Awaiting market dataPeer 28p
Grading rule: BUY/OVERWEIGHT scores Correct when forward return > 0; UNDERWEIGHT/SELL when < 0; HOLD is Neutral. Window uses 5 US trading sessions after the rating entry close vs benchmark SPY. Scorecard computed 2026-06-17T07:48:16.820994+00:00.
5D move
—
2026-06-16 → awaiting
Outcome
Awaiting market data
5D trend
-0.69%
Vol (20D ann.)
+23.93%
vs SPY: -2.49%
Close 90.62 → — (USD, vendor closes)
Publish QC
passedExpandCollapse
Publish QC
passed
Pipeline fingerprint 2f45a102687f75c0
Trace 36e7507e…
No QC issues recorded.